AI Summary

New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12–15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated dose (MTD) of tirzepatide are seven times more likely to maintain that weight loss by continuing on MTD than those who stop treatment, while those who switch to a lower dose of 5 mg are four times more likely to maintain weight loss than those who stop.

AI summaries can be wrong sometimes—always verify important details using the source article.